chartexchange

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

GlobeNewswire Inc. | Oct 5, 2026 10:00 AM EDT

– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction –

Read original article